Michelle Gleeson

1.8k total citations · 2 hit papers
42 papers, 1.3k citations indexed

About

Michelle Gleeson is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Michelle Gleeson has authored 42 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 8 papers in Genetics. Recurrent topics in Michelle Gleeson's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (5 papers). Michelle Gleeson is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral-associated cancers and disorders (5 papers). Michelle Gleeson collaborates with scholars based in United States, United Kingdom and Switzerland. Michelle Gleeson's co-authors include Mark D. Danese, Robert I. Griffiths, Quan V. Doan, Joseph Mıkhael, Shoshana Colman, Rohit Varma, Chantal Dolan, Adam Turpcu, Jennifer Fine and Julie K. Bower and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michelle Gleeson

39 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of and Risk Factors for Diabetic Macular Edema in the United States

2014 298 citations Quan V. Doan, Michelle Gleeson et al. profile →
Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease

2019 199 citations Deborah P. Lubeck, Mark D. Danese et al. profile →

Peers

Michelle Gleeson

OPHTH

RNMI

GENET

HEMAT

ONCOL

Arijit Ganguli United States

Yi‐Ching Hsieh United States

Jean Pierre Daurès France

Lidwine W. Tick Netherlands

Andrew Koenig United States

Martina Biggioggero Italy

Stephen K. Gruschkus United States

A. Aupérin France

David Carruthers United Kingdom

Y. Benhamou France

Arijit Ganguli United States

Michelle Gleeson

167 ×0.4

OPHTH

49 ×0.1

RNMI

83 ×0.3

GENET

191 ×0.8

HEMAT

126 ×0.6

ONCOL

Citations per year, relative to Michelle Gleeson Michelle Gleeson (= 1×) peers Arijit Ganguli

Countries citing papers authored by Michelle Gleeson

Since Specialization

Citations

This map shows the geographic impact of Michelle Gleeson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Gleeson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Gleeson more than expected).

Fields of papers citing papers by Michelle Gleeson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Gleeson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Gleeson. The network helps show where Michelle Gleeson may publish in the future.

Co-authorship network of co-authors of Michelle Gleeson

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Gleeson. A scholar is included among the top collaborators of Michelle Gleeson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Gleeson. Michelle Gleeson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Danese, Mark D., Eduard Sidelnikov, Guillermo Villa, et al.. (2022). Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. BMJ Open. 12(4). e055015–e055015.

Danese, Mark D., Deborah P. Lubeck, Vasily Belozeroff, et al.. (2020). Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients. American Journal of Nephrology. 51(10). 815–822. 3 indexed citations

Danese, Mark D., Aaron J. Katz, Karynsa Cetin, et al.. (2019). Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. Leukemia & lymphoma. 60(8). 2015–2024. 5 indexed citations

Richards, Donald, Maen Hussein, Steven McCune, et al.. (2018). What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.. Journal of Clinical Oncology. 36(15_suppl). e20567–e20567. 1 indexed citations

Danese, Mark D., et al.. (2017). Treatment patterns and survival among patients with extensive disease small cell lung cancer (ED-SCLC).. Journal of Clinical Oncology. 35(15_suppl). e20026–e20026. 1 indexed citations

Danese, Mark D., Michelle Gleeson, Lucie Kutikova, et al.. (2016). Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open. 6(8). e011805–e011805. 31 indexed citations

Danese, Mark D., Carolina Reyes, Michelle Gleeson, et al.. (2016). Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. Medical Care. 54(4). 343–349. 20 indexed citations

Lowe, Kimberly A., et al.. (2016). Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States. Journal of Gastrointestinal Cancer. 47(2). 168–181. 8 indexed citations

Danese, Mark D., Robert I. Griffiths, Michelle Gleeson, et al.. (2016). Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leukemia & lymphoma. 58(5). 1094–1104. 26 indexed citations

10.

Danese, Mark D., Erica A. Voss, Michelle Gleeson, et al.. (2015). Feasibility of Converting the Medicare Synthetic Public Use Data Into a Standardized Data Model for Clinical Research Informatics.. AMIA. 1 indexed citations

11.

Chia, Victoria M., Cynthia D. O’Malley, Mark D. Danese, et al.. (2013). Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecologic Oncology. 129(2). 346–352. 23 indexed citations

12.

Griffiths, Robert I., Michelle Gleeson, Mark D. Danese, & Anthony O’Hagan. (2012). Inverse Probability Weighted Least Squares Regression in the Analysis of Time-Censored Cost Data: An Evaluation of the Approach Using SEER-Medicare. Value in Health. 15(5). 656–663. 18 indexed citations

13.

Griffiths, Robert I., Mark D. Danese, Michelle Gleeson, & José M Valderas. (2012). Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare. BMC Cancer. 12(1). 613–613. 21 indexed citations

14.

Griffiths, Robert I., Michelle Gleeson, Joseph Mıkhael, Martin Dreyling, & Mark D. Danese. (2012). Comparative effectiveness and cost of adding rituximab to first‐line chemotherapy for elderly patients diagnosed with diffuse large B‐cell lymphoma. Cancer. 118(24). 6079–6088. 26 indexed citations

15.

Griffiths, Robert I., Richard Barron, Michelle Gleeson, et al.. (2011). Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer. PharmacoEconomics. 30(2). 103–118. 10 indexed citations

16.

Griffiths, Robert I., Michelle Gleeson, Kevin Knopf, & Mark D. Danese. (2010). Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 10(1). 625–625. 34 indexed citations

17.

Griffiths, Robert I., Michelle Gleeson, Carolina Reyes, Kevin Knopf, & Mark D. Danese. (2010). Survival in elderly follicular lymphoma patients who receive frontline chemo‐immunotherapy. American Journal of Hematology. 85(12). 963–967. 6 indexed citations

18.

Bradbury, Brian D., Mark D. Danese, Michelle Gleeson, & Cathy W. Critchlow. (2009). Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL. Clinical Journal of the American Society of Nephrology. 4(3). 630–637. 44 indexed citations

19.

Danese, Mark D., Karla Lindquist, Michelle Gleeson, Robert Deuson, & Joseph Mıkhael. (2009). Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. American Journal of Hematology. 84(10). 631–635. 37 indexed citations

20.

Doan, Quan V., Michelle Gleeson, John Kim, et al.. (2007). Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Current Medical Research and Opinion. 23(7). 1561–1569. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact